Lagevrio (molnupiravir) has a complicated track record. Its effectiveness depends heavily on who takes it and whether they’ve been vaccinated. In early trials of unvaccinated, high-risk patients, it showed a meaningful reduction in hospitalization and death. But in the largest trial of vaccinated adults, over 25,000 people, it failed to reduce hospitalizations or deaths at all. The drug does appear to speed recovery and remains useful for specific populations, particularly older and unvaccinated patients.
What the Largest Trials Found
The most important evidence comes from the PANORAMIC trial, published in The Lancet, which enrolled over 25,700 high-risk adults in the community. Ninety-four percent had received at least three doses of a COVID-19 vaccine. Participants either took Lagevrio twice daily for five days alongside their usual care, or received usual care alone.
The results were disappointing for the drug’s headline claim. Hospitalizations or deaths occurred in 1% of both groups: 105 out of 12,529 in the Lagevrio group versus 98 out of 12,525 in the usual care group. Statistically, that’s no difference. The trial concluded plainly that molnupiravir did not reduce COVID-related hospitalizations or death among high-risk vaccinated adults.
There was a silver lining. People who took Lagevrio recovered faster, maintained that recovery more consistently, and needed fewer doctor visits afterward. So while the drug didn’t prevent the worst outcomes in this population, it did shorten illness.
Where Lagevrio Works Better
The picture changes significantly for older adults and those who haven’t been fully vaccinated. A large retrospective study from Hong Kong, conducted during the Omicron BA.2 wave, tracked hospitalized COVID-19 patients who didn’t need supplemental oxygen at admission. Among those patients, Lagevrio cut the death rate nearly in half. At 28 days, 7.5% of Lagevrio recipients had died compared to 14.9% of patients who didn’t receive an antiviral. The hazard ratio for death from any cause was 0.48, meaning roughly a 52% reduction in mortality risk.
Lagevrio recipients in that study were also less likely to see their disease worsen (40% lower risk) and less likely to need supplemental oxygen (31% lower risk). By day 28, about 84% of Lagevrio patients had been discharged from the hospital compared to 75% of controls.
Subgroup analyses from the same study pointed to an important pattern: the benefit was concentrated in patients older than 65 and those who were not fully vaccinated. Younger patients and fully vaccinated individuals didn’t see a statistically significant benefit, which aligns with the PANORAMIC findings. This suggests Lagevrio is most valuable for the people at highest baseline risk of severe disease.
How It Compares to Paxlovid
Paxlovid (nirmatrelvir-ritonavir) consistently outperforms Lagevrio in head-to-head comparisons. In a study of COVID-19 patients with advanced kidney disease, Paxlovid users had a 37.6% lower risk of death and a 21.8% lower risk of hospitalization compared to Lagevrio users over 90 days. The Hong Kong data told a similar story: both drugs reduced disease progression by comparable amounts (Paxlovid by 43%, Lagevrio by 40%), but Paxlovid generally edged ahead on mortality outcomes.
That said, Paxlovid interacts with a long list of other medications, which makes it unsuitable for some patients. Lagevrio has far fewer drug interactions, so it serves as an important alternative when Paxlovid isn’t an option.
Side Effects
Lagevrio is well tolerated. In the Phase 3 trial, the most common side effects were diarrhea (3%), nausea (2%), dizziness (1%), and headache (1%). All were mild or moderate. Vomiting, rash, and hives occurred less frequently. Serious adverse reactions were rare, and the side effect profile is considerably simpler than Paxlovid’s, which can cause a strong bitter taste and has more gastrointestinal effects.
Timing and Who It’s For
Lagevrio needs to be started within five days of symptom onset. The FDA’s authorization specifies taking it as soon as possible after a COVID-19 diagnosis. The standard course is five days, taken twice daily. It’s authorized for adults at high risk of progressing to severe COVID-19, particularly when other antiviral options like Paxlovid aren’t appropriate.
The World Health Organization issued a conditional recommendation for molnupiravir, meaning it’s recommended under specific circumstances rather than broadly for all COVID-19 patients. That conditional status reflects the mixed evidence: strong benefits for vulnerable populations, minimal benefit for vaccinated, lower-risk individuals.
The Bottom Line on Effectiveness
Lagevrio’s effectiveness is real but narrow. If you’re over 65, unvaccinated or undervaccinated, or unable to take Paxlovid, the drug can meaningfully reduce your risk of severe illness and death. For younger, fully vaccinated adults, the evidence suggests it speeds recovery by a modest amount but won’t change your odds of hospitalization. It’s a useful tool in the COVID-19 treatment toolkit, but not the most powerful one available.